Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/88489
Title: Semiconducting photothermal nanoagonist for remote-controlled specific cancer therapy
Authors: Zhen, Xu
Xie, Chen
Jiang, Yuyan
Ai, Xiangzhao
Xing, Bengang
Pu, Kanyi
Keywords: Ion Channels
Photothermal Nanoagonists
Issue Date: 2018
Source: Zhen, X., Xie, C., Jiang, Y., Ai, X., Xing, B., & Pu, K. (2018). Semiconducting Photothermal Nanoagonist for Remote-Controlled Specific Cancer Therapy. Nano Letters, 18(2), 1498-1505.
Series/Report no.: Nano Letters
Abstract: Nanomedicine have shown success in cancer therapy, but the pharmacological actions of most nanomedicine are often nonspecific to cancer cells because of utilization of the therapeutic agents that induce cell apoptosis from inner organelles. We herein report the development of semiconducting photothermal nanoagonists that can remotely and specifically initiate the apoptosis of cancer cells from cell membrane. The organic nanoagonists comprise semiconducting polymer nanoparticles (SPNs) and capsaicin (Cap) as the photothermally responsive nanocarrier and the agonist for activation of transient receptor potential cation channel subfamily V member 1 (TRPV1), respectively. Under multiple NIR laser irradiation at the time scale of seconds, the nanoagonists can repeatedly and locally release Cap to multiply activate TRPV1 channels on the cellular membrane; the cumulative effect is the overinflux of ions in mitochondria followed by the induction of cell apoptosis specifically for TRPV1-postive cancer cells. Multiple transient activation of TRPV1 channels is essential to induce such a cell death both in vitro and in vivo because both free Cap and simple Cap-encapsulated nanoparticles fail to do so. The photothermally triggered release also ensures a high local concentration of the TRPV1 agonist at tumor site, permitting specific cancer cell therapy at a low systemic administration dosage. Our study thus demonstrates the first example of ion-channel-specific and remote-controlled drug-delivery system for cancer cell therapy.
URI: https://hdl.handle.net/10356/88489
http://hdl.handle.net/10220/44640
ISSN: 1530-6984
DOI: http://dx.doi.org/10.1021/acs.nanolett.7b05292
Rights: © 2018 American Chemical Society. This is the author created version of a work that has been peer reviewed and accepted for publication by Nano Letters, American Chemical Society. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1021/acs.nanolett.7b05292].
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SPMS Journal Articles

Files in This Item:
File Description SizeFormat 
Nano Letters Manuscript.pdf1.35 MBAdobe PDFThumbnail
View/Open

Google ScholarTM

Check

Altmetric

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.